154 related articles for article (PubMed ID: 11162933)
1. Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring?
Graham JD; Bain DL; Richer JK; Jackson TA; Tung L; Horwitz KB
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):255-9. PubMed ID: 11162933
[TBL] [Abstract][Full Text] [Related]
2. Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer.
Graham JD; Bain DL; Richer JK; Jackson TA; Tung L; Horwitz KB
Steroids; 2000; 65(10-11):579-84. PubMed ID: 11108862
[TBL] [Abstract][Full Text] [Related]
3. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT.
Jackson TA; Richer JK; Bain DL; Takimoto GS; Tung L; Horwitz KB
Mol Endocrinol; 1997 Jun; 11(6):693-705. PubMed ID: 9171233
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors.
Takimoto GS; Graham JD; Jackson TA; Tung L; Powell RL; Horwitz LD; Horwitz KB
J Steroid Biochem Mol Biol; 1999; 69(1-6):45-50. PubMed ID: 10418980
[TBL] [Abstract][Full Text] [Related]
5. Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor.
Morrison AJ; Herrera RE; Heinsohn EC; Schiff R; Osborne CK
Mol Endocrinol; 2003 Aug; 17(8):1543-54. PubMed ID: 12730327
[TBL] [Abstract][Full Text] [Related]
6. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen.
Smith CL; Nawaz Z; O'Malley BW
Mol Endocrinol; 1997 Jun; 11(6):657-66. PubMed ID: 9171229
[TBL] [Abstract][Full Text] [Related]
7. p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells.
Carroll JS; Lynch DK; Swarbrick A; Renoir JM; Sarcevic B; Daly RJ; Musgrove EA; Sutherland RL
Cancer Res; 2003 Aug; 63(15):4322-6. PubMed ID: 12907598
[TBL] [Abstract][Full Text] [Related]
8. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer.
Fleming FJ; Hill AD; McDermott EW; O'Higgins NJ; Young LS
J Clin Endocrinol Metab; 2004 Jan; 89(1):375-83. PubMed ID: 14715875
[TBL] [Abstract][Full Text] [Related]
9. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation.
Chan CM; Martin LA; Johnston SR; Ali S; Dowsett M
J Steroid Biochem Mol Biol; 2002 Aug; 81(4-5):333-41. PubMed ID: 12361723
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
Kurokawa H; Arteaga CL
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
[TBL] [Abstract][Full Text] [Related]
11. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells.
Gaddy VT; Barrett JT; Delk JN; Kallab AM; Porter AG; Schoenlein PV
Clin Cancer Res; 2004 Aug; 10(15):5215-25. PubMed ID: 15297425
[TBL] [Abstract][Full Text] [Related]
12. Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT.
Keeton EK; Brown M
Mol Endocrinol; 2005 Jun; 19(6):1543-54. PubMed ID: 15802375
[TBL] [Abstract][Full Text] [Related]
13. The silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor is required for full estrogen receptor alpha transcriptional activity.
Peterson TJ; Karmakar S; Pace MC; Gao T; Smith CL
Mol Cell Biol; 2007 Sep; 27(17):5933-48. PubMed ID: 17591692
[TBL] [Abstract][Full Text] [Related]
14. A new MCF-7 breast cancer cell line resistant to the arzoxifene metabolite desmethylarzoxifene.
Freddie CT; Christensen GL; Lykkesfeldt AE
Mol Cell Endocrinol; 2004 May; 220(1-2):97-107. PubMed ID: 15196704
[TBL] [Abstract][Full Text] [Related]
15. Estrogen response element-dependent regulation of transcriptional activation of estrogen receptors alpha and beta by coactivators and corepressors.
Klinge CM; Jernigan SC; Mattingly KA; Risinger KE; Zhang J
J Mol Endocrinol; 2004 Oct; 33(2):387-410. PubMed ID: 15525597
[TBL] [Abstract][Full Text] [Related]
16. Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer.
Murphy LC; Leygue E; Niu Y; Snell L; Ho SM; Watson PH
Br J Cancer; 2002 Dec; 87(12):1411-6. PubMed ID: 12454770
[TBL] [Abstract][Full Text] [Related]
17. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
Osborne CK; Bardou V; Hopp TA; Chamness GC; Hilsenbeck SG; Fuqua SA; Wong J; Allred DC; Clark GM; Schiff R
J Natl Cancer Inst; 2003 Mar; 95(5):353-61. PubMed ID: 12618500
[TBL] [Abstract][Full Text] [Related]
18. Antiestrogens--tamoxifen, SERMs and beyond.
Dhingra K
Invest New Drugs; 1999; 17(3):285-311. PubMed ID: 10665480
[TBL] [Abstract][Full Text] [Related]
19. Full activation of estrogen receptor alpha activation function-1 induces proliferation of breast cancer cells.
Fujita T; Kobayashi Y; Wada O; Tateishi Y; Kitada L; Yamamoto Y; Takashima H; Murayama A; Yano T; Baba T; Kato S; Kawabe Y; Yanagisawa J
J Biol Chem; 2003 Jul; 278(29):26704-14. PubMed ID: 12738788
[TBL] [Abstract][Full Text] [Related]
20. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen.
Girault I; Lerebours F; Amarir S; Tozlu S; Tubiana-Hulin M; Lidereau R; Bièche I
Clin Cancer Res; 2003 Apr; 9(4):1259-66. PubMed ID: 12684393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
